Transforming the precision of cancer imaging, surgery and therapy
Our vision is to give everyone diagnosed with cancer their best chance to become cancer free
Transforming the precision of cancer imaging, surgery and therapy
Our vision is to give everyone diagnosed with cancer their best chance to become cancer free
We believe that by bringing together world-class expertise in chemistry, bioengineering and medicine we can identify solutions that will transform the accuracy of early cancer staging. Ensuring that no cancer goes undetected has the potential to allow surgeons and pathologists to maximise the use of their skills, support less-invasive procedures, and improve outcomes for patients.
What gives us purpose
We all know someone – a friend or a family member – who is facing a cancer diagnosis. And, collectively, we have witnessed too many people close to us find hope that they are cancer free, only to be told later that ‘the cancer is back’.
We believe that by bringing together world-class expertise in chemistry, bioengineering and medicine we can identify solutions that will transform the staging and treatment of early stage cancers. Ensuring that no cancer goes undetected has the potential to allow surgeons and pathologists to maximise the use of their skills, support less-invasive procedures, and improve outcomes for patients.
Ultimately, for our families, and yours, we are driven to continue pushing the boundaries of nanotechnology to help make sure no one dies unnecessarily because cancer was missed.
Our history
Core IP University of Sydney
1990
Research into medical applications
2000
Collaboration in head and neck cancer
2010
Collaboration between the University of South Australia, University of Adelaide, and Royal Adelaide Hospital
Ferronova incorporated investment
2016
Preclinical validation studies
2016 - 2020
Start colorectal trial
March/July 2021
Ashford Hospital & Ingham Institute
Start Oral Cancer first in human trial
2020
Royal Adelaide Hospital and Uni of Adelaide (Completed June 2022)
BMTH grant for colorectal
trial
2020
Ingham Institute, UniSA, UniSyd
Series A Funding
2020
Led by Uniseed
FerroTrace®-FAPI research program
2019
Collaboration between NHMRC Grants, University of South Australia, UNSW, and Uni Q
Start Breast Cancer Study
June 2021
Collaboration between The Royal Melbourne Hospital and Peter MacCallum Cancer Centre.
Agreement with
Diagnostic
Green
2022
Agreement with leading provider of trusted high-quality fluorescence agents for clinicians worldwide.
Our core values
what we stand for
We solve big problems
Difficult projects don’t scare us
We value relationships
Respectful and considerate – always
We’re an open book
Transparency in all that we do
We care
Our desire to help comes from the heart
Who
backs us
Ferronova seed funding has been supported by a range of investors-including Uniseed and Artesian Venture Partners.
The South Australian Government have also provided grant funding to enable the further progression of clinical trials.